Farmacologiay Toxicologia©
2 (13) 2023 : 001-002 • Commentary Article

Advancements in Pharmacological Screenings: Techniques, Technologies, and Applications for Drug Discovery

Ujvyid Tanyehi*

Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC 27606, USA

AUTHORS' CONTRIBUTION: (A) Study Design · **(B)** Data Collection . **(C)** Statistical Analysis · **(D)** Data Interpretation · **(E)** Manuscript Preparation · **(F)** Literature Search · **(G)** No Fund Collection

ABSTRACT

Pharmacological screenings play a critical role in drug discovery and development. These screenings involve the testing of large libraries of compounds to identify potential therapeutic candidates for various diseases. In this manuscript, we review the different types of pharmacological screenings, their advantages and limitations, and their applications in drug discovery. We also discuss the various techniques and technologies used in pharmacological screenings, including high-throughput screening and virtual screening. Finally, we highlight some recent advancement in the field of pharmacological screenings and their potential impact on drug discovery.

Keywords: Pharmacological screenings; Drug discovery; High-throughput screening; Virtual screening; Compound libraries

Address for correspondence:

Dr. Ujvyid Tanyehi,
Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC 27606, USA
E-mail: U_Tanyehi@gmail.com

Word count: 815 **Tables:** 00 **Figures:** 00 **References:** 10

Received: 03.04.2023, Manuscript No. ipft-23-13753; **Editor assigned:** 05.04.2023, PreQC No. P-13753; **Reviewed:** 19.04.2023, QC No. Q-13753; **Revised:** 22.04.2023, Manuscript No. R-13753; **Published:** 28.04.2023

INTRODUCTION

Pharmacological screenings are a crucial step in the drug discovery process, allowing researchers to identify potential therapeutic candidates for a wide range of diseases. These screenings typically involve the testing of large libraries of compounds, ranging from natural products to synthetic molecules, to identify those that exhibit specific pharmacological activities. The results of these screenings can then be used to guide further drug development and optimization [1, 2]

DISCUSSION

Types of pharmacological screenings

There are several types of pharmacological screenings, each with its own advantages and limitations. These include target-based screenings, phenotypic screenings, and *in vivo* screenings [3, 4].

Target-based screenings involve the use of assays that measure the interaction between a compound and a specific target, such as a receptor or enzyme. These assays are highly specific and can be used to identify compounds that bind to a particular target with high affinity. Target-based screenings are often used in the early stages of drug discovery to identify compounds that have the potential to modulate a specific target.

Phenotypic screenings, on the other hand, involve the use of assays that measure a specific cellular response, such as cell proliferation or apoptosis. These screenings are less specific than target-based screenings but can identify compounds with a broader range of pharmacological activities. Phenotypic screenings are often used in later stages of drug discovery, where the goal is to identify compounds that exhibit a desired biological effect in cells or tissues [5, 6].

In vivo screenings involve the testing of compounds in animal models to evaluate their efficacy and safety. These screenings are the most physiologically relevant and can provide valuable information about the pharmacokinetics and pharmacodynamics of a compound. In vivo screenings are typically used in the later stages of drug development, after a compound has been identified as a potential therapeutic candidate [7].

Techniques and technologies used in pharmacological screenings

Pharmacological screenings rely on a variety of techniques and technologies to identify potential therapeutic candidates. High-throughput screening (HTS) is a widely

used technique that allows for the rapid testing of large libraries of compounds. HTS typically involves the use of robotics and automation to perform assays in a highly parallelized manner, allowing for the screening of hundreds of thousands of compounds in a relatively short amount of time.

Virtual screening is another technique that has become increasingly popular in recent years. Virtual screening involves the use of computer algorithms to screen large libraries of compounds in silico, based on their predicted binding affinity to a target of interest. Virtual screening can be used to identify potential therapeutic candidates before they are synthesized, reducing the time and cost associated with traditional screening approaches [8].

Recent advancements in pharmacological screenings

Recent advancements in pharmacological screenings have led to the development of new screening platforms and technologies. For example, organ-on-a-chip technology allows for the testing of compounds in three-dimensional microenvironments that more closely resemble human tissues. This technology has the potential to improve the accuracy and relevance of *in vitro* screenings [9].

Another recent advancement is the use of machine learning algorithms to analyse large datasets generated by pharmacological screenings. Machine learning algorithms can be used to identify patterns and relationships in the data that may be missed by traditional analysis methods, allowing for the identification of new therapeutic candidates [10].

CONCLUSION

Pharmacological screenings play a critical role in drug discovery and development, allowing researchers to identify potential therapeutic candidates for various diseases. The different types of pharmacological screenings, their advantages and limitations, and their applications in drug discovery have been reviewed in this manuscript. The various techniques and technologies used in pharmacological screenings, including high-throughput screening and virtual screening, have been discussed. Finally, some recent advancement in the field of pharmacological screenings and their potential impact on drug discovery has been highlighted.

ACKNOWLEDGMENT

None

CONFLICT OF INTEREST

No conflict of interest to declare about this work.

REFERENCES

1. **Tomlin JL, Sturgeon C, Pead MJ, et al.** Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. *Vet Rec*.2000:147(2): 129-32.
2. **Psychas V, Loukopoulos P, Polizopoulou ZS, et al.** Multilobular tumour of the caudal cranium causing severe cerebral and cerebellar compression in a dog. *J Vet Sci*. 2009; 10(5): 81-3.
3. **Loukopoulos P, Thornton JR, Robinson WF.** Clinical and pathologic relevance of p53 index in canine osseous tumors. *Veterinary Pathology*.2003; 40(8): 237-48.
4. **Bech-Nielsen S, Haskins ME.** Frequency of osteosarcoma among first-degree relatives of St Bernard dogs. *J Natl Cancer Inst*.2003; 60(4): 349-53.
5. **Wilkins RM, Cullen JW, Odom L.** Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. *Ann Surg Oncol*.2003; 10(4): 498-507.
6. **Kundu ZS.** Classification, imaging, biopsy and staging of osteosarcoma. *Indian J Orthop*.2014;48(2): 238-46.
7. **Papalas JA, Balmer NN, Wallace C.** Ossifying dermatofibroma with osteoclast-like giant cells: report of a case and literature review. *Am J Dermatopathol*.2009; 31(5): 379-83.
8. **Gelberg KH, Fitzgerald EF, Hwang SA.** Fluoride exposure and childhood osteosarcoma: a case-control study. *Am J Public Health*.1995; 85(2): 1678-83.
9. **Luetke A, Meyers PA, Lewis A**. Osteosarcoma treatment where do we stand a state of the art review. *Cancer Treat Rev*. 2014; 40(5): 523-532.
10. **Dhaliwal J, Sumathi VP, Grimer RJ.** Radiation-induced periosteal osteosarcoma (PDF). *Grand Rounds*.2009; 10(1): 13-18.